SmallCaps
ASX:TRIHealth Care Equipment & ServicesHealth Care Technology

TrivarX Ltd

$0.015
Day Range
$0.015 – $0.015
52 Week Range
$0.008 – $0.035
Volume
97.18K
Avg Volume (10D)
519.54K
Market Cap
$17.31M

Price Chart

OHLC · volume · moving averages

$0.015-$0.008 (-34.78%)over 6M
Hi$0.032Lo$0.014
Price-sensitive newsVolumePrev close · 52W range

Market Statistics

Today's trading range

Open
$0.015
Previous Close
$0.015
Day High
$0.015
Day Low
$0.015
52 Week High
$0.035
52 Week Low
$0.008

Valuation

Fundamental multiples

Market Cap
17.31M
Shares Outstanding
1.15B
Price to Book
0.73

Trading Activity

Volume & order book

Volume
97.18K
Value Traded
1.46K
Bid
$0.015 × 1,649
Ask
$0.017 × 348,407

Performance

Returns across timeframes

1 Day
7.14%
5 Day
-6.25%
13 Week
-51.61%
52 Week
66.67%
YTD
-21.05%

Technical Indicators

Momentum & moving averages

RSI (14)
41.83
50-Day SMA
$0.019
200-Day SMA
$0.021

— From the desk

Latest News

TrivarX Engages Beyond Drug Development to Progress Stabl-Im Safety Trial
Biotechnology

TrivarX Engages Beyond Drug Development to Progress Stabl-Im Safety Trial

TrivarX engages Beyond Drug Development to push Stabl-Im Phase 1 safety trial, targeting H2 2026 start and data for regulatory progress.

TrivarX Reports Strong US Veteran Trial Results Supporting Objective Depression Screening
Biotechnology

TrivarX Reports Strong US Veteran Trial Results Supporting Objective Depression Screening

TrivarX (ASX: TRI) has delivered positive results from a US-based clinical trial that demonstrate clinically meaningful, objective detection of current major depressive episodes in veterans using the company’s single-lead electrocardiogram technology.

TrivarX to Acquire Stabl-Im Diagnostic Technology for Early Detection of Metastatic Brain Tumours
Biotechnology

TrivarX to Acquire Stabl-Im Diagnostic Technology for Early Detection of Metastatic Brain Tumours

TrivarX (ASX: TRI) has announced plans to acquire novel Stabl-Im metastatic brain technology and associated stable isotope cancer diagnostic intellectual property from Australian company Nucleics. Stabl-Im represents a potential breakthrough in the safe and non-invasive detection of brain cancers and metastases using standard magnetic resonance imaging (MRI) equipment to visualise and monitor tumour growth without the […]

TrivarX R&D program advances MEB-001 algorithm for screening of depressive episodes
Biotechnology

TrivarX R&D program advances MEB-001 algorithm for screening of depressive episodes

An extensive research and development (R&D) program by mental health technology company TrivarX (ASX: TRI) has advanced the company’s proprietary artificial intelligence-backed algorithm MEB-001 for the screening of current major depressive episode (cMDE). The algorithm can accurately conduct sleep staging and screen for cMDE in subjects through a single-channel electrocardiogram, using heart rate and heart […]